A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients

Introduction:Current clinical research has reported the effectiveness and safety of venetoclax in combination with hypomethylating agents (VEN-HMA) in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Thus, this study aimed to examine the effectiveness and saf...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Ludan Zhang, Rui Ge, Deng Pan, Pengjie Yue, Jingwen Zhang, Renjie Bian, Xiaojing Yan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-05-01
Subjects:	myelodysplastic syndromes chronic myelomonocytic leukemia venetoclax hypomethylating agents real-world study
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1265840/full